Profile: Ark Therapeutics Group PLC (AKT.L)

AKT.L on London Stock Exchange

0.54GBp
28 Mar 2014
Price Change (% chg)

-- (--)
Prev Close
0.54p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
0
52-wk High
0.59p
52-wk Low
0.28p

Search Stocks
Ark Therapeutics Group plc is engaged in the provision of contract development and manufacturing services to the pharmaceutical and biotech industry. The Company’s business activity includes the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The products in the Company focuses to partner with include Neuropilin-1 antagonists for anti-tumour therapy; EG011 for refractory angina; EG013 for fetal growth restriction; EG016 for peripheral vascular disease; Cerepro for malignant glioma, and Trinam for maintaining vascular access grafts. Ark Therapeutics Oy is the Company’s subsidiary, which is engaged the provision of contract development and manufacturing services to the pharmaceutical and biotech industry. The Company conducts research at its facilities in Kuopio Finland, at University College London.

Company Address

Ark Therapeutics Group PLC

85 Tottenham Court Road
LONDON   ENG   W1T 4TQ
P: +4420.70021005
F: +4420.72683100

Search Stocks